{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:12:26Z","timestamp":1789589546142,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["222038"],"award-info":[{"award-number":["222038"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["254478"],"award-info":[{"award-number":["254478"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It is uncertain whether medication with metformin decreases the risk of liver cancer. This study aimed to test the hypotheses that use of metformin decreases the risk of developing both main subtypes of liver cancer, that is, hepatocellular carcinoma and intrahepatic cholangiocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This nationwide population-based cohort study included all individuals who had dispensed anti-diabetic medications between 2005 and 2018 in Sweden, except for those with a history of viral hepatitis. We assessed the associations between metformin use and the risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by using Cox regression, adjusted for age, sex, calendar year, smoking-related diagnoses, alcohol-related diagnoses, non-alcoholic fatty liver disease, use of non-steroidal anti-inflammatory drugs, and use of statins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 744\u00a0173 participants, 526\u00a0859 (70.8%) were metformin users. During the follow-up of a median of 6.8 (maximum 13.5) years, 1622 participants developed hepatocellular carcinoma and 319 developed intrahepatic cholangiocarcinoma. Metformin use was associated with a slightly increased risk of hepatocellular carcinoma (hazard ratio [HR] = 1.15, 95% confidence interval [CI] = 1.02 to 1.30), but a decreased risk in participants with a prior diagnosis of obesity (HR = 0.56, 95% CI = 0.34 to 0.90). No statistically significant association was observed for intrahepatic cholangiocarcinoma (HR = 0.77, 95% CI = 0.59 to 1.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study found an increased risk of hepatocellular carcinoma associated with metformin use overall, while suggesting a decreased risk in individuals with obesity. No clear association was observed for intrahepatic cholangiocarcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkag053","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:45:15Z","timestamp":1779363915000},"source":"Crossref","is-referenced-by-count":1,"title":["Metformin use and the risk of liver cancer in a Swedish population-based cohort study"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5705-9413","authenticated-orcid":false,"given":"Yongying","family":"Huang","sequence":"first","affiliation":[{"name":"Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou,","place":["China"]},{"name":"Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giola","family":"Santoni","sequence":"additional","affiliation":[{"name":"Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Sparrelid","sequence":"additional","affiliation":[{"name":"Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4270-1281","authenticated-orcid":false,"given":"Shao-Hua","family":"Xie","sequence":"additional","affiliation":[{"name":"Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"School of Public Health, Fujian Medical University , Fuzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"2026061006211697200_pkag053-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026061006211697200_pkag053-B2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.32723","article-title":"International trends in hepatocellular carcinoma incidence, 1978-2012","volume":"147","author":"Petrick","year":"2020","journal-title":"Int J Cancer"},{"key":"2026061006211697200_pkag053-B3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12889-022-12867-w","article-title":"Global pattern of trends in incidence, mortality, and mortality-to-incidence ratio rates related to liver cancer, 1990-2019: a longitudinal analysis based on the Global Burden of Disease study","volume":"22","author":"Amini","year":"2022","journal-title":"BMC Public Health"},{"key":"2026061006211697200_pkag053-B4","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"key":"2026061006211697200_pkag053-B5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J Hepatol"},{"key":"2026061006211697200_pkag053-B6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver cancer: connections with obesity, fatty liver, and cirrhosis","volume":"67","author":"Marengo","year":"2016","journal-title":"Annu Rev Med"},{"key":"2026061006211697200_pkag053-B7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026061006211697200_pkag053-B8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"2026061006211697200_pkag053-B9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"2026061006211697200_pkag053-B10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1749-6632.2011.06285.x","article-title":"Diabetes, cancer, and metformin: connections of metabolism and cell proliferation","volume":"1243","author":"Gallagher","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"2026061006211697200_pkag053-B11","doi-asserted-by":"crossref","first-page":"15330338221119743","DOI":"10.1177\/15330338221119743","article-title":"Cancer of the liver and its relationship with diabetes mellitus","volume":"21","author":"Onikanni","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"2026061006211697200_pkag053-B12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/hepr.13912","article-title":"Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma","volume":"53","author":"Ono","year":"2023","journal-title":"Hepatol Res"},{"key":"2026061006211697200_pkag053-B13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3350\/cmh.2024.0038","article-title":"Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy","volume":"30","author":"Tsai","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"2026061006211697200_pkag053-B14","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients","volume":"96","author":"Nkontchou","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061006211697200_pkag053-B15","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3390\/v15122451","article-title":"Metformin and hepatocellular carcinoma risk reduction in diabetic patients with chronic hepatitis C: fact or fiction?","volume":"15","author":"Sacco","year":"2023","journal-title":"Viruses"},{"key":"2026061006211697200_pkag053-B16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2026061006211697200_pkag053-B17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MEG.0000000000002503","article-title":"Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis","volume":"35","author":"Laffusa","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026061006211697200_pkag053-B18","doi-asserted-by":"crossref","first-page":"e023155","DOI":"10.1136\/bmjopen-2018-023155","article-title":"Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)","volume":"9","author":"Xie","year":"2019","journal-title":"BMJ Open"},{"key":"2026061006211697200_pkag053-B19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026061006211697200_pkag053-B20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"2026061006211697200_pkag053-B21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1186\/s12879-022-07886-2","article-title":"Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018","volume":"22","author":"Colombe","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026061006211697200_pkag053-B22","doi-asserted-by":"crossref","first-page":"e001076","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstrom","year":"2012","journal-title":"BMJ Open"},{"key":"2026061006211697200_pkag053-B23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/apt.17371","article-title":"Meta-analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin","volume":"57","author":"Zeng","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061006211697200_pkag053-B24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/hep.26092","article-title":"Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk","volume":"57","author":"Chaiteerakij","year":"2013","journal-title":"Hepatology"},{"key":"2026061006211697200_pkag053-B25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1055-9965.EPI-20-1322","article-title":"Aspirin, statins, non-aspirin NSAIDs, metformin, and the risk of biliary cancer: a Swedish Population-Based Cohort Study","volume":"31","author":"Marcano-Bonilla","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026061006211697200_pkag053-B26","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/s41598-021-81172-0","article-title":"Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells","volume":"11","author":"Di Matteo","year":"2021","journal-title":"Sci Rep"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkag053\/68383650\/pkag053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/3\/pkag053\/68383650\/pkag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/3\/pkag053\/68383650\/pkag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:21:27Z","timestamp":1781086887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkag053\/8692836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkag053","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,9]]},"article-number":"pkag053"}}